Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-05-20, Stock:ABBV, The news for the past five days is as follows:
2019-05-13: NEWS1: AbbVie- Unique Mix of Growth, Yield and Value.
2019-05-14: NEWS1: AbbVie Rises 3%.NEWS2: MC10, Inc. and AbbVie (NYSE:ABBV) Announce Clinical Trials in Multiple Sclerosis Using the BioStamp nPoint® System.NEWS3: Here are the stocks to buy if an all-out U.S.-China trade war erupts, says Goldman.NEWS4: AbbVie stock up 1.3% after announcing resolution to litigation over Humira in the U.S..NEWS5: AbbVie Resolves HUMIRA® (adalimumab) U.S. Patent Litigation with Boehringer Ingelheim.NEWS6: AbbVie to Present at the UBS Global Healthcare Conference.
2019-05-15: NEWS1: Health Care Sector Update for 05/15/2019: ABBV,ACB,ACB.TO,ECOR,IMGN.NEWS2: Health Care Sector Update for 05/15/2019: ABBV,ACB,ACB.TO,ECOR,IMGN.NEWS3: AbbVie Announces US FDA Approval of VENCLEXTA® (venetoclax) as a Chemotherapy-Free Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia Patients.NEWS4: 3 Reasons Why AbbVie (ABBV) Is a Great Growth Stock.NEWS5: 3 Reasons Why AbbVie (ABBV) Is a Great Growth Stock.NEWS6: Why AbbVie (ABBV) is a Great Dividend Stock Right Now.NEWS7: Why AbbVie (ABBV) is a Great Dividend Stock Right Now.NEWS8: AbbVie Settles Humira Litigation With Boehringer Ingelheim.NEWS9: AbbVie Settles Humira Litigation With Boehringer Ingelheim.NEWS10: Why AbbVie (ABBV) is a Great Dividend Stock Right Now.NEWS11: 3 Reasons Why AbbVie (ABBV) Is a Great Growth Stock.NEWS12: AbbVie Settles Humira Litigation With Boehringer Ingelheim.NEWS13: PRESS DIGEST -Wall Street Journal - May 15.
2019-05-16: nan
2019-05-17: NEWS1: Roche Gets FDA Nod for Venclexta Plus Gazyva to Treat CLL.NEWS2: AbbVie halts enrollment after brain cancer trial misses goal, shares fall.NEWS3: AbbVie stock down 1.8% in premarket trade after failure of glioblastoma drug trial.NEWS4: AbbVie Provides Update on Depatuxizumab Mafodotin (Depatux-M), an Investigational Medicine for Newly Diagnosed Glioblastoma, an Aggressive Form of Brain Cancer.NEWS5: Pharma Stock Roundup: FDA Okays Line Extensions of LLY, PFE, ABBV Cancer Drugs.

Answer: Rise